| 1. |
|
|
| 2. |
- Byrne, Julianne, et al.
(author)
-
The PanCareSurFup consortium : research and guidelines to improve lives for survivors of childhood cancer
- 2018
-
In: European Journal of Cancer. - : ELSEVIER SCI LTD. - 0959-8049 .- 1879-0852. ; 103:Nov, s. 238-248
-
Journal article (peer-reviewed)abstract
- Background: Second malignant neoplasms and cardiotoxicity are among the most serious and frequent adverse health outcomes experienced by childhood and adolescent cancer survivors (CCSs) and contribute significantly to their increased risk of premature mortality. Owing to differences in health-care systems, language and culture across the continent, Europe has had limited success in establishing multi-country collaborations needed to assemble the numbers of survivors required to clarify the health issues arising after successful cancer treatment. PanCareSurFup (PCSF) is the first pan-European project to evaluate some of the serious long-term health risks faced by survivors. This article sets out the overall rationale, methods and preliminary results of PCSF. Methods: The PCSF consortium pooled data from 13 cancer registries and hospitals in 12 European countries to evaluate subsequent primary malignancies, cardiac disease and late mortality in survivors diagnosed between ages 0 and 20 years. In addition, PCSF integrated radiation dosimetry to sites of second malignancies and to the heart, developed evidence-based guidelines for long-term care and for transition services, and disseminated results to survivors and the public. Results: We identified 115,596 individuals diagnosed with cancer, of whom 83,333 were 5-year survivors and diagnosed from 1940 to 2011. This single data set forms the basis for cohort analyses of subsequent malignancies, cardiac disease and late mortality and case-control studies of subsequent malignancies and cardiac disease in 5-year survivors. Conclusions: PCSF delivered specific estimates of risk and comprehensive guidelines to help survivors and care-givers. The expected benefit is to provide every European CCS with improved access to care and better long-term health.
|
|
| 3. |
- Grabow, Desiree, et al.
(author)
-
The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer : a cohort from 12 European countries
- 2018
-
In: European Journal of Epidemiology. - : Springer Science and Business Media LLC. - 0393-2990 .- 1573-7284. ; 33:3, s. 335-349
-
Journal article (peer-reviewed)abstract
- Childhood cancer survivors face risks from a variety of late effects, including cardiac events, second cancers, and late mortality. The aim of the pan-European PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) Consortium was to collect data on incidence and risk factors for these late effects among childhood cancer survivors in Europe. This paper describes the methodology of the data collection for the overall PanCareSurFup cohort and the outcome-related cohorts. In PanCareSurFup 13 data providers from 12 countries delivered data to the data centre in Mainz. Data providers used a single variable list that covered all three outcomes. After validity and plausibility checks data was provided to the outcome-specific working groups. In total, we collected data on 115,596 patients diagnosed with cancer from 1940 to 2011, of whom 83,333 had survived 5 years or more. Due to the eligibility criteria and other requirements different numbers of survivors were eligible for the analysis of each of the outcomes. Thus, 1014 patients with at least one cardiac event were identified from a cohort of 39,152 5-year survivors; for second cancers 3995 survivors developed at least one second cancer from a cohort of 71,494 individuals, and from the late mortality cohort of 79,441 who had survived at least 5 years, 9247 died subsequently. Through the close cooperation of many European countries and the establishment of one central data collection and harmonising centre, the project succeeded in generating the largest cohort of children with cancer to date.
|
|
| 4. |
|
|
| 5. |
- Linares-Pastén, Javier A., et al.
(author)
-
Three-dimensional structures and functional studies of two GH43 arabinofuranosidases from Weissella sp. strain 142 and Lactobacillus brevis
- 2017
-
In: The FEBS Journal. - : Wiley. - 1742-464X. ; 284:13, s. 2019-2036
-
Journal article (peer-reviewed)abstract
- Arabinofuranosidases degrade arabinose-containing oligo and polysaccharides, releasing l-arabinose, which is a potentially useful sugar, shown to reduce glycemic response under certain conditions. Arabinofuranosidases (Arafs) are frequently found in GH43, one of the most common GH-families encoded in genomes in gut microbiota, and hence it is of interest to increase understanding of the function of these enzymes in species occurring in the gut. Here we have produced, characterized and solved the three-dimensional structures, at 1.9 and 2.0 Å resolution respectively, of two homologous GH43 enzymes, classified under subfamily 26, from Lactobacillus brevis DSM1269 (LbAraf43) and Weissella strain 142 (WAraf43), respectively. The enzymes, with 74% sequence identity to each other, are composed of a single catalytic module with a β-propeller structure typical of GH43, and an active-site pocket with three identifiable subsites (−1, +1, and +2). According to size exclusion chromatography, native WAraf43 is a dimer, while LbAraf43 is a tetramer in solution. Both of them show activity with similar catalytic efficiency on 1,5-α-l-arabinooligosaccharides with a degree of polymerization (DP) of 2–3. Activity is restricted to substrates of low DP, and the reason for this is believed to be an extended loop at the entrance to the active site, creating interactions in the +2 subsite. Database: Structural data are available in the PDB under the accession numbers 5M8B (LbAraf43) and 5M8E (WAraf43).
|
|
| 6. |
|
|
| 7. |
- Wilhelmson, Mari, et al.
(author)
-
Hospitalizations in Long-term Survivors of Childhood AML Treated with Allogeneic HSCT - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) Study
- 2019
-
In: 38th NOPHO Annual meeting. Aalborg, Denmark 3-7 May.
-
Conference paper (other academic/artistic)abstract
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is effective in treating childhood acute myeloid leukemia (AML) but the long-term disease burden may be increased. In a population-based study, the standardized hospitalization rates ratios (SHRR) and absolute excess risks for disease specific hospitalizations were evaluated in 5-year survivors of AML treated at 0-17 years of age according to the NOPHO-AML protocols in four Nordic countries during 1984-2005. In total, 229 eligible AML survivors were identified in the NOPHO-AML database and the treatment data of 196 survivors could be linked to 5-year follow-up data in national hospital registries. After a median follow-up time of 12 (range 5–28) years, 35 out of the 97 survivors treated with allo-HSCT had been hospitalized (SHRR 2.8 (95% CI 2.0– 4.0) with increased risk for hospitalizations due to cardiovascular 8.7 (3.9–19), endocrine 12 (6.7–22), pulmonary 3.0 (1.8–5.2), gastrointestinal 4.0 (2.4–6.7), infectious 3.1 (1.3–7.6), neurological 4.4 (2.1–9.2) and uro-genital system conditions 2.9 (1.3–6.4). In comparison, after a median follow-up time of 11 (range 5–28) years, 21 out of the 99 survivors treated with chemotherapy alone had been hospitalized; SHRR 1.4 (0.9–2.1). Our results indicate that hospitalization rates are significantly increased in long-term survivors of childhood AML if treated with allo-HSCT but not in survivors treated with chemotherapy only.
|
|
